[Form 3] Liminatus Pharma, Inc. Initial Statement of Beneficial Ownership
Liminatus Pharma, Inc. (LIMN) Form 3 shows an initial statement of beneficial ownership filed for Iris Acquisition Holdings LLC in connection with an event dated 04/30/2025. The reporting entity lists a total of 6,900,000 shares of Common Stock beneficially owned in a direct ownership form. The filing identifies the reporting person as related to the issuer with the label string that includes Director. The document is signed by Sumit Mehta, Authorized Representative with a signature date of 08/15/2025. No derivative securities are reported and no exercise or conversion terms are listed.
Liminatus Pharma, Inc. (LIMN) — il Modulo 3 riporta una dichiarazione iniziale di titolarità effettiva presentata da Iris Acquisition Holdings LLC relativa a un evento datato 04/30/2025. L'entità che effettua la segnalazione indica il possesso beneficiario di un totale di 6.900.000 azioni di Common Stock in forma di proprietà diretta. La segnalazione identifica la persona collegata all'emittente con l'indicazione Director. Il documento è firmato da Sumit Mehta, Authorized Representative con data di firma 08/15/2025. Non sono riportati titoli derivati né termini di esercizio o conversione.
Liminatus Pharma, Inc. (LIMN) — el Formulario 3 muestra una declaración inicial de propiedad beneficiaria presentada por Iris Acquisition Holdings LLC en relación con un evento fechado el 04/30/2025. La entidad que reporta indica la propiedad beneficiaria de un total de 6.900.000 acciones de Common Stock en forma de titularidad directa. La presentación identifica a la persona vinculada al emisor con la etiqueta Director. El documento está firmado por Sumit Mehta, Authorized Representative con fecha de firma 08/15/2025. No se informan valores derivados ni se especifican términos de ejercicio o conversión.
Liminatus Pharma, Inc. (LIMN)의 Form 3에는 04/30/2025자로 발생한 사건과 관련해 Iris Acquisition Holdings LLC가 제출한 최초의 실소유자 보고가 기재되어 있습니다. 보고기관은 직접 보유 형태로 총 6,900,000주 보통주(Common Stock)를 실질적으로 보유하고 있다고 명시했습니다. 보고서에는 보고인이 발행회사와의 관련성으로 Director라는 표기가 포함되어 있습니다. 문서는 Sumit Mehta, Authorized Representative가 서명했으며 서명일은 08/15/2025입니다. 파생증권은 보고되지 않았고 행사 또는 전환 조건도 기재되어 있지 않습니다.
Liminatus Pharma, Inc. (LIMN) — le formulaire 3 présente une déclaration initiale de propriété bénéficiaire déposée par Iris Acquisition Holdings LLC en lien avec un événement daté du 04/30/2025. L'entité déclarant indique détenir au total 6 900 000 actions de Common Stock sous une forme de propriété directe. Le dépôt identifie la personne déclarée comme liée à l'émetteur avec la mention Director. Le document est signé par Sumit Mehta, Authorized Representative et daté du 08/15/2025. Aucun titre dérivé n'est signalé et aucun terme d'exercice ou de conversion n'est précisé.
Liminatus Pharma, Inc. (LIMN) — das Formular 3 enthält eine Erstmeldung des wirtschaftlich Berechtigten durch Iris Acquisition Holdings LLC im Zusammenhang mit einem Ereignis vom 04/30/2025. Die meldende Stelle gibt insgesamt 6.900.000 Aktien der Common Stock im Wege des direkten Eigentums als wirtschaftlich zugehörig an. In der Einreichung wird die meldende Person im Verhältnis zum Emittenten mit der Bezeichnung Director geführt. Das Dokument ist unterzeichnet von Sumit Mehta, Authorized Representative mit Unterzeichnungsdatum 08/15/2025. Es werden keine Derivate gemeldet und keine Ausübungs- oder Umwandlungsbedingungen angegeben.
- Clear initial disclosure of beneficial ownership satisfying Section 16 reporting for the 6,900,000-share position
- No derivative securities reported, indicating the position is solely common stock with no attached options or warrants disclosed
- None.
Insights
TL;DR: Initial disclosure of a sizable direct stake of 6.9M shares in LIMN, reported on Form 3; no derivatives disclosed.
The Form 3 documents an initial beneficial ownership filing for Iris Acquisition Holdings LLC reporting 6,900,000 shares of common stock as directly owned. The filing records an event date of 04/30/2025 and a signature by an authorized representative on 08/15/2025. There are no derivative positions reported, so the stake is purely equity with no listed options, warrants, or convertibles attached in this filing. From an investor-disclosure perspective, this meets Section 16 initial reporting requirements by identifying a principal holder and the size of the position.
TL;DR: Form 3 notifies the market of a new direct stake; governance implications depend on context not provided here.
The filing names Iris Acquisition Holdings LLC and contains the relationship string that includes Director, indicating a governance linkage noted on the form. The report does not provide additional governance details, such as whether the holder will join the board or any agreements tied to the shares. Absent further disclosures or amendments, this Form 3 serves as a baseline ownership disclosure without additional governance commitments or restrictions described.
Liminatus Pharma, Inc. (LIMN) — il Modulo 3 riporta una dichiarazione iniziale di titolarità effettiva presentata da Iris Acquisition Holdings LLC relativa a un evento datato 04/30/2025. L'entità che effettua la segnalazione indica il possesso beneficiario di un totale di 6.900.000 azioni di Common Stock in forma di proprietà diretta. La segnalazione identifica la persona collegata all'emittente con l'indicazione Director. Il documento è firmato da Sumit Mehta, Authorized Representative con data di firma 08/15/2025. Non sono riportati titoli derivati né termini di esercizio o conversione.
Liminatus Pharma, Inc. (LIMN) — el Formulario 3 muestra una declaración inicial de propiedad beneficiaria presentada por Iris Acquisition Holdings LLC en relación con un evento fechado el 04/30/2025. La entidad que reporta indica la propiedad beneficiaria de un total de 6.900.000 acciones de Common Stock en forma de titularidad directa. La presentación identifica a la persona vinculada al emisor con la etiqueta Director. El documento está firmado por Sumit Mehta, Authorized Representative con fecha de firma 08/15/2025. No se informan valores derivados ni se especifican términos de ejercicio o conversión.
Liminatus Pharma, Inc. (LIMN)의 Form 3에는 04/30/2025자로 발생한 사건과 관련해 Iris Acquisition Holdings LLC가 제출한 최초의 실소유자 보고가 기재되어 있습니다. 보고기관은 직접 보유 형태로 총 6,900,000주 보통주(Common Stock)를 실질적으로 보유하고 있다고 명시했습니다. 보고서에는 보고인이 발행회사와의 관련성으로 Director라는 표기가 포함되어 있습니다. 문서는 Sumit Mehta, Authorized Representative가 서명했으며 서명일은 08/15/2025입니다. 파생증권은 보고되지 않았고 행사 또는 전환 조건도 기재되어 있지 않습니다.
Liminatus Pharma, Inc. (LIMN) — le formulaire 3 présente une déclaration initiale de propriété bénéficiaire déposée par Iris Acquisition Holdings LLC en lien avec un événement daté du 04/30/2025. L'entité déclarant indique détenir au total 6 900 000 actions de Common Stock sous une forme de propriété directe. Le dépôt identifie la personne déclarée comme liée à l'émetteur avec la mention Director. Le document est signé par Sumit Mehta, Authorized Representative et daté du 08/15/2025. Aucun titre dérivé n'est signalé et aucun terme d'exercice ou de conversion n'est précisé.
Liminatus Pharma, Inc. (LIMN) — das Formular 3 enthält eine Erstmeldung des wirtschaftlich Berechtigten durch Iris Acquisition Holdings LLC im Zusammenhang mit einem Ereignis vom 04/30/2025. Die meldende Stelle gibt insgesamt 6.900.000 Aktien der Common Stock im Wege des direkten Eigentums als wirtschaftlich zugehörig an. In der Einreichung wird die meldende Person im Verhältnis zum Emittenten mit der Bezeichnung Director geführt. Das Dokument ist unterzeichnet von Sumit Mehta, Authorized Representative mit Unterzeichnungsdatum 08/15/2025. Es werden keine Derivate gemeldet und keine Ausübungs- oder Umwandlungsbedingungen angegeben.
FAQ
What stake did Iris Acquisition Holdings LLC disclose in Liminatus Pharma (LIMN)?
When is the event date and when was the Form 3 signed for LIMN?
Does the Form 3 report any derivative securities for LIMN?
Who signed the Form 3 filing for Iris Acquisition Holdings LLC?
Does the Form 3 indicate any governance role for the reporting person at LIMN?
